Beyondspring (NASDAQ:BYSI)‘s stock had its “buy” rating restated by analysts at Maxim Group in a research report issued on Wednesday. They presently have a $52.00 target price on the stock. Maxim Group’s price target would indicate a potential upside of 99.92% from the stock’s previous close.
The analysts wrote, “On January 29th, BeyondSpring hosted a KOL call to discuss its lead asset, Plinabulin. Dr. Douglas Blayney, a founding member of the NCCN neutropenia management guideline panel, spoke on the call regarding Plinabulin and the ongoing phase 2/3 trial, Study 105 for the prevention of docetaxel chemotherapy-induced neutropenia (CIN).””
A number of other research analysts have also recently weighed in on the stock. HC Wainwright set a $60.00 target price on shares of Beyondspring and gave the company a “buy” rating in a research note on Friday, December 15th. Zacks Investment Research upgraded shares of Beyondspring from a “sell” rating to a “hold” rating in a research note on Tuesday, January 9th. Finally, Seaport Global Securities started coverage on shares of Beyondspring in a research note on Tuesday, December 5th. They issued a “buy” rating and a $56.00 target price on the stock. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Beyondspring presently has a consensus rating of “Buy” and an average price target of $54.50.
Beyondspring (NASDAQ:BYSI) last released its earnings results on Thursday, November 9th. The company reported ($0.68) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.69) by $0.01. sell-side analysts expect that Beyondspring will post -4.41 earnings per share for the current fiscal year.
A hedge fund recently bought a new stake in Beyondspring stock. Tanaka Capital Management Inc. purchased a new stake in Beyondspring Inc (NASDAQ:BYSI) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 21,322 shares of the company’s stock, valued at approximately $914,000. Beyondspring accounts for about 2.1% of Tanaka Capital Management Inc.’s investment portfolio, making the stock its 16th largest holding. Tanaka Capital Management Inc. owned approximately 0.10% of Beyondspring at the end of the most recent quarter. Hedge funds and other institutional investors own 1.22% of the company’s stock.
BeyondSpring Inc is a global clinical-stage biopharmaceutical company. The Company is focused on the development of cancer therapies. The Company is engaged in advancing its lead product, Plinabulin, into a Phase II/III clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase II/III clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia, and a Phase III clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC).
Receive News & Ratings for Beyondspring Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beyondspring and related companies with MarketBeat.com's FREE daily email newsletter.